Esparma Gmbh

Other

Imtm Gmbh

Serumwerk Bernburg Ag

Gerhard Fries

Dieter Koegst

Wolfgang A Wohlrab

Reinhard Neubert

Christoph Huschka

Siegfried Ansorge

Peter-J&uuml;rgen M&uuml;ller

J&ouml;rg-Herman Ozegowski

Rudolf-Giesbert Alken

Michael Täger

Michael Taeger

J&uuml;rgen Schneider

The invention relates to the use of the combination of n-lipoic acid and effectors of the glutathione metabolism for the treatment of disturbances of the cellular thiol status and accompanying disorders in kidney replacement therapy.

Use of a medicament containing an effector of the glutathione metabolism together with &#x3b1;-lipoic acid in kidney replacement therapy

The invention relates to a medicament containing an effector of the glutathione metabolism together with &#x3b1;-lipoic acid for treating diabetes mellitus. This medicament enables disturbances of the thiol-disulfide status or those that occur, for example, in diabetes mellitus to be treated simultaneously, separately or in a temporally graduated manner.

Medicament containing an effector of the glutathione metabolism together with &#x3b1;-lipoic acid for treating diabetes mellitus

The invention relates to an agent for treating skin diseases and/or functional disorders of the skin on the basis of different medicaments and/or auxiliary substances through promotion of penetration from topical formulations into the skin. According to the invention, the agent is composed of a hyaluronate lyase produced by microbial means and a medicament, preferably a hydrophilic medicament and/or auxiliary substances in different galenic formulations including colloidal carrier systems. The areas of application for the invention in human and veterinary medicament relate to the treatment, prophylaxis and/or metaphylaxis of skin diseases, functional disorders of the skin, the processes of skin ageing and dry skin conditions.

Hyaluronate lyase used for promoting penetration in topical agents

The invention relates to an agent for the treatment, prophylaxis and metaphylaxis of functional and structural disorders of the skin caused by external factors. The agent contains a hyaluronic acid partially digested with a microbiological hyaluronate lyase. The hyaluronic acid fragment mixture is incorporated in different galenic formulations to which other hydrophilic and/or lipophilic active substances and/or auxiliary substances can be added. Fields of application of the invention in human and veterinary medicine relate to the treatment and/or the prophylaxis of skin damage caused by environmental factors including UV, dry skin conditions and skin ageing.

Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis

Lipid metabolic disorders, such as hyperlipidemia or hyperlipoproteinemia can be treated by administering to an afflicted individual an effective amount of 5-(1,2-dithiolan-3-yl) valeric acid (&agr;-lipoic acid) or one of its physiologically acceptable salts. Pharmaceutical compositions containing (&agr;-lipoic acid) and methods for making such compositions also are disclosed.

Treatment of lipid metabolic disorders using 5-(1,2-dithiolan-3-yl) valeric acid (&agr;-lipoic acid) or its physiologically compatible salts

The invention relates to a pharmaceutical preparation in a make-up which is suited for external application and which contains a dithranol derivative as an active ingredient.

Growing community of inventors

Wahlitz, Germany

Gerhard Fries